News Quantified

RVNC – revance therapeutics, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Revance Therapeutics, Inc. (NASDAQ: RVNC) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.

Shareholders that lost money on Revance Therapeutics, Inc.(RVNC) should contact Levi & Korsinsky about Securities Fraud Investigation - RVNC

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Revance Therapeutics, Inc. - RVNC

Revance Therapeutics, Inc. (NASDAQ: RVNC) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.

Revance Therapeutics, Inc. (NASDAQ: RVNC) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.

19.7%

BEAT

-22.6%

BEAT

26.1%

BEAT

Needham & Company LLC

Needham & Company LLC

Form 4 Revance Therapeutics, For: Nov 18 Filed by: Hollander David

Form 8-K Revance Therapeutics, For: Nov 19

Form 8-K Revance Therapeutics, For: Nov 12

Form 10-Q Revance Therapeutics, For: Sep 30

Form 8-K Revance Therapeutics, For: Nov 07

Top News Gainers

1/9 Revance to Participate in the 38th Annual J.P. Morgan Healthcare Conference 18.3%

5/9 Revance Therapeutics, Inc. (RVNC) on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] 16.5%

10/14 Revance Appoints Mark J. Foley as President and CEO, Replacing Dan Browne 15.1%

4/2 Revance Therapeutics Inc (NASDAQ: RVNC) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 8.4%

12/2 Revance Therapeutics Inc (NASDAQ: RVNC) is now covered by analysts at Goldman Sachs Group Inc. They set a "buy" rating and a $25.00 price target on the stock. 8.2%

1/11 Did Changing Sentiment Drive Revance Therapeutics's (NASDAQ:RVNC) Share Price Down By 25%? [Yahoo! Finance News] 7.7%

8/8 Revance Therapeutics Inc (NASDAQ: RVNC) had its "outperform" rating re-affirmed by analysts at William Blair. 7.2%

1/15 Revance Therapeutics Inc (NASDAQ: RVNC) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $24.00 price target on the stock. 5.3%

10/15 Form 8-K Revance Therapeutics, For: Oct 11 4.7%

7/29 Revance to Release Second Quarter 2019 Financial Results on Monday, August 5, 2019 4.6%

Top News Decliners

4/1 Revance Therapeutics Inc (NASDAQ: RVNC) had its "buy" rating re-affirmed by analysts at Mizuho. They now have a $35.00 price target on the stock. -14.9%

12/3 Revance Announces Proposed Public Offering of Common Stock -14.6%

3/17 Form 4 Revance Therapeutics, For: Mar 15 Filed by: Joshi Abhay -13.7%

3/13 Form SC 13G Revance Therapeutics, Filed by: GIC Private Ltd -12.0%

2/25 Revance Therapeutics Inc (NASDAQ: RVNC) had its price target raised by analysts at Needham & Company LLC from $32.00 to $36.00. They now have a "buy" rating on the stock. -9.6%

2/10 Form 8-K Revance Therapeutics, For: Feb 10 -9.2%

4/15 Revance Therapeutics Inc (NASDAQ: RVNC) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $36.00 price target on the stock. -7.3%

2/26 Form 10-K Revance Therapeutics, For: Dec 31 -7.2%

4/30 Revance to Release First Quarter 2020 Financial Results on Thursday, May 7, 2020 -6.5%

8/27 Form 8-K Revance Therapeutics, For: Aug 22 -6.1%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day